Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
935 Main Street
Waltham
Massachusetts
MA 02451
USA
Tel: +1 781 899 7755 Fax: +1 781 899 2814
www.aquabounty.com
Key Financials
Share Price (as at 19.07.10): 10.25p
Market Cap: £4.38m
Listing on AIM: 20 Mar 2006
Stock trading symbol: ABTX
FTSE Sector: Pharmaceuticals & Biotechnology
AquaBounty Technologies is a biotechnology company
focused on enhancing productivity in the aquaculture
market.
Its AquAdvantage® Salmon product consists of
Key benefits of AquAdvantage® Salmon: standard Atlantic salmon eggs that include a gene from
Chinook salmon, which enables the fish to grow to
• Reduced pressure on wild fish stocks: By providing a ready source market size in half the time of conventional Atlantic
of faster‐growing fish, salmon grown from AquAdvantage® eggs can salmon.
help reduce pressure on wild fish stocks suffering from over‐fishing The product is currently going through the approval
• Job creation: Aquaculture provides opportunities for U.S. jobs by process of the US Food & Drug Administration.
potentially contributing to a newly re‐invigorated domestic industry, Significantly, the fish would be the first food from a
as opposed to importing salmon from other parts of the world transgenic animal to be approved by the FDA.
The company, under the name A/F Protein, acquired a
• Economic benefits: Faster growth means a more efficient use of license to the AquAdvantage® technology in 1996 from
capital, reduced feed costs and less time to market the University of Toronto and Memorial University of
• Lower carbon footprint: AquAdvantage® salmon are grown in on‐ Newfoundland. A/F Protein was separated…The
shore facilities that can be built close to consumer markets – whereas AquAdvantage division was separated from the
fresh and frozen fish require energy intensive transportation combined company in 2000 to become AquaBounty
Farms, which was amended to AquaBounty
FDA approval:
Technologies four years later.
• Completion of all outstanding FDA submissions and requests for
AquaBounty is listed on the London Stock Exchange’s
information in 2009
AIM and is headquartered in Boston, USA, with its test
• Successful FDA inspection of the Company’s production facility
facilities located on Prince Edward Island, Canada.
• In March 2010, the FDA issued the conclusion of its review of the
AAS “Claim Validation” study – indicating the remaining sections Key Management:
would be issued in due course
Ronald L. Stotish – Executive Director, President and
• Recently received letters from the Center for Veterinary Medicine Chief Executive Officer
(FDA sub‐body) confirming AquaBounty has passed three of seven
Ronald L. Stotish, Ph.D. was appointed an Executive
parts of their examination of the application
Director, President and CEO of AquaBounty
• The company believes the reviews for the remaining four parts of the
Technologies in May 2008. Dr. Stotish joined
CVM examination are very nearly complete and expect a successful
AquaBounty Technologies in 2006 as Vice President for
outcome in the near future, with the holding of a Veterinary Medical
Regulatory Affairs, and most recently was Senior Vice
Advisory Committee meeting as the next step in the formal process
President for R&D and Regulatory Affairs. Prior to
for the FDA approval of the product
joining AquaBounty, Dr. Stotish was Executive Vice
Commercial market test: President for R&D at MetaMorphix, Inc. He began his
• Performance of AAS in commercial market test met expectations career in research at Merck. Dr. Stotish has degrees in
• Established relationships with producers/authorities in several biochemistry and over 38 years experience in the
countries who have appropriate production resources and are discovery, development, and commercialization of new
interested in testing the product animal health products.
• R&D continues on next generation products David A. Frank – Chief Financial Officer
David Frank was appointed CFO in October 2007.
For further information: Previously he served as President and General Manager
Harry Chathli / Claire Norbury / Neil Thapar of TekCel LLC, a subsidiary of Magellan Biosciences,
Corfin Public Relations Ltd. after serving as Magellan’s CFO since the company’s
12th Floor, The Broadgate Tower, 20 Primrose Street, founding in 2004 and as TekCel’s CFO since 2003. Mr.
London, EC2A 2EW, United Kingdom Frank has over 25 years of financial‐management
Tel: +44 (0)20 7596 2860 Fax: +44 (0)20 7596 2868
experience, including as CFO of SmartEnergy and
www.corfinpr.com
corporate controller for Moldflow. He has a BS in finance
and accounting from Boston College and an MBA from
Babson College.